Репозиторий OAI—PMH
Репозиторий Российская Офтальмология Онлайн по протоколу OAI-PMH
Конференции
Офтальмологические конференции и симпозиумы
Видео
Видео докладов
Реферат RUS | Реферат ENG | Литература | Полный текст |
УДК: | 617.7-007.681 DOI: https:/doi.org/10.25276/0235-4160-2021-2-94-99 |
Сидорова А.В., Журавлев А.С., Старостина А.В., Елисеева М.А.
Эффективность и безопасность различных лекарственных форм бримонидина при глаукоме и офтальмогипертензии
1. Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global Prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11): 2081–2090. doi: 10.1016/j.ophtha.2014.05.013
2. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008;53(6):S3 10. doi: 10.1016/j.survophthal.2008.08.006
3. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120(10): 1268–1279. doi: 10.1001/archopht.120.10.1268
4. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6): 701–713; 829–830. doi: 10.1001/archopht.120.6.701
5. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126(4): 487–497. doi: 10.1016/S0002-9394(98)00223-2
6. Hedman K, Alm A. A Pooled-Data Analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;10(2): 95–104. doi: 10.1177/112067210001000201
7. Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2(4): 337–346. doi: 10.2147/tcrm.2006.2.4.337
8. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(6): S93–105. doi:10.1016/j.survophthal.2008.08.004
9. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11): 1943–1953. doi: 10.1016/S0161-6420(01)00873-9
10. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: A review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996;41: S19–26. doi: 10.1016/S0039-6257(96)82028-5
11. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113(12): 1514–1517. doi: 10.1001/archopht.1995.01100120044006
12. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128(1): 8–14. doi: 10.1016/S0002-9394(99)00076-8
13. Kesler A, Shemesh G, Rothkoff L, Lazar M. Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size. J Cataract Refract Surg. 2004;30(8): 1707–1710. doi: 10.1016/j.jcrs.2004.02.043
14. Niyadurupola N, Broadway DC. Pigment dispersion syndrome and pigmentary glaucoma – a major review. Clin Exp Ophthalmol. 2008;36(9): 868–882. doi: 10.1111/j.1442-9071.2009.01920.x
15. Acheampong AA, Shackleton M, John B, Burke J, Wheeler L, Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat Eyes. Drug Metab Dispos. 2002;30(4): 421–429. doi: 10.1124/dmd.30.4.421
16. Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000;1(4): 815–834. doi: 10.1517/14656566.1.4.815
17. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-Year study of brimonidine twice daily in glaucoma and ocular hypertension: A controlled, randomized, multicenter clinical trial. Arch Ophthalmol. 1997;115(7): 847–852. doi: 10.1001/archopht.1997.01100160017002
18. David R. Brimonidine (Alphagan®): A clinical profile four years after launch. Eur J Ophthalmol. 2001;11(2_suppl): 72–77. doi: 10.1177/112067210101102S10
19. Javitt J, Goldberg I. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine outcomes study group II. J Glaucoma. 2000;9(5): 398–408. doi: 10.1097/00061198-200010000-00009
20. Stewart WC, Sharpe ED, Harbin TS, Pastor SA, Day DG, Holmes KT. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol. 2000;129(6): 723–727. doi: 10.1016/S0002-9394(00)00381-0
21. Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Therap. 2001;23(4):604–619. doi: 10.1016/S0149-2918(01)80064-3
22. Carrasco FC, Arias Puente A, Garcia Saenz MC, Villarejo Diaz-Maroto I. Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers. Arch Soc Esp Oftalmol. 2004;79(4): 163–168.
23. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23(5): 490–496. doi: 10.1097/01.ico.0000116526.57227.82
24. Bonniard AA, Yeung JY, Chan CC, Birt CM. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016;12(11): 1279–1289. doi: 10.1080/17425255.2016.1209481
25. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11(2): 119–126.
26. Dong JQ, Babusis DM, Welty DF, Acheampong AA, Tang-Liu D, Whitcup SM. Effects of the preservative Purite® on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther. 2004;20(4): 285–292. doi: 10.1089/1080768041725326
27. Mundorf T, Williams R, Whitcup S, Felix C, Batoosingh A. A 3-month comparison of efficacy and safety of brimonidine-Purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2003;19(1): 37–44. doi: 10.1089/108076803762718097
28. Konstas AGP, Karabatsas CH, Lallos N, Georgiadis N, Kotsimpou A, Stewart JA. 24-hour intraocular pressures with brimonidine Purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology. 2005;112(4): 603–608. doi: 10.1016/j.ophtha.2004.11.032
29. Adkins JC, Balfour JA. Brimonidine. Drugs Aging. 1998;12(3): 225–241. doi: 10.2165/00002512-199812030-00005
30. Sullivan-Mee M, Pensyl D, Alldredge B, Halverson K, Gerhardt G, Qualls C. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations. J Ocul Pharmacol Therap. 2010;26(4): 355–360. doi: 10.1089/jop.2009.0153
31. Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW. Alpha(2)-adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther. 2001;296(1): 216–223.
32. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42(12): 2849–2855.
33. Mayor-Torroglosa S, Villa PD la, Rodriguez ME, Lopez-Herrera MPL, Aviles-Trigueros M, Garcia-Aviles A. Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidine. Invest Ophthalmol Vis Sci. 2005;46(10): 3825–3835. doi: 10.1167/iovs.05-0392
34. Tsai J-C, Chang H-W. Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study. J Ocular Pharmacol Ther. 2005;21(6): 475–482. doi: 10.1089/jop.2005.21.475
35. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol. 2011;151(4): 671–681. doi: 10.1016/j.ajo.2010.09.026
36. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005;62(7): 691–699. doi: 10.1093/ajhp/62.7.691
2. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008;53(6):S3 10. doi: 10.1016/j.survophthal.2008.08.006
3. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120(10): 1268–1279. doi: 10.1001/archopht.120.10.1268
4. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6): 701–713; 829–830. doi: 10.1001/archopht.120.6.701
5. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126(4): 487–497. doi: 10.1016/S0002-9394(98)00223-2
6. Hedman K, Alm A. A Pooled-Data Analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;10(2): 95–104. doi: 10.1177/112067210001000201
7. Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2(4): 337–346. doi: 10.2147/tcrm.2006.2.4.337
8. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(6): S93–105. doi:10.1016/j.survophthal.2008.08.004
9. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11): 1943–1953. doi: 10.1016/S0161-6420(01)00873-9
10. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: A review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996;41: S19–26. doi: 10.1016/S0039-6257(96)82028-5
11. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113(12): 1514–1517. doi: 10.1001/archopht.1995.01100120044006
12. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128(1): 8–14. doi: 10.1016/S0002-9394(99)00076-8
13. Kesler A, Shemesh G, Rothkoff L, Lazar M. Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size. J Cataract Refract Surg. 2004;30(8): 1707–1710. doi: 10.1016/j.jcrs.2004.02.043
14. Niyadurupola N, Broadway DC. Pigment dispersion syndrome and pigmentary glaucoma – a major review. Clin Exp Ophthalmol. 2008;36(9): 868–882. doi: 10.1111/j.1442-9071.2009.01920.x
15. Acheampong AA, Shackleton M, John B, Burke J, Wheeler L, Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat Eyes. Drug Metab Dispos. 2002;30(4): 421–429. doi: 10.1124/dmd.30.4.421
16. Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000;1(4): 815–834. doi: 10.1517/14656566.1.4.815
17. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-Year study of brimonidine twice daily in glaucoma and ocular hypertension: A controlled, randomized, multicenter clinical trial. Arch Ophthalmol. 1997;115(7): 847–852. doi: 10.1001/archopht.1997.01100160017002
18. David R. Brimonidine (Alphagan®): A clinical profile four years after launch. Eur J Ophthalmol. 2001;11(2_suppl): 72–77. doi: 10.1177/112067210101102S10
19. Javitt J, Goldberg I. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine outcomes study group II. J Glaucoma. 2000;9(5): 398–408. doi: 10.1097/00061198-200010000-00009
20. Stewart WC, Sharpe ED, Harbin TS, Pastor SA, Day DG, Holmes KT. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol. 2000;129(6): 723–727. doi: 10.1016/S0002-9394(00)00381-0
21. Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Therap. 2001;23(4):604–619. doi: 10.1016/S0149-2918(01)80064-3
22. Carrasco FC, Arias Puente A, Garcia Saenz MC, Villarejo Diaz-Maroto I. Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers. Arch Soc Esp Oftalmol. 2004;79(4): 163–168.
23. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23(5): 490–496. doi: 10.1097/01.ico.0000116526.57227.82
24. Bonniard AA, Yeung JY, Chan CC, Birt CM. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016;12(11): 1279–1289. doi: 10.1080/17425255.2016.1209481
25. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11(2): 119–126.
26. Dong JQ, Babusis DM, Welty DF, Acheampong AA, Tang-Liu D, Whitcup SM. Effects of the preservative Purite® on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther. 2004;20(4): 285–292. doi: 10.1089/1080768041725326
27. Mundorf T, Williams R, Whitcup S, Felix C, Batoosingh A. A 3-month comparison of efficacy and safety of brimonidine-Purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2003;19(1): 37–44. doi: 10.1089/108076803762718097
28. Konstas AGP, Karabatsas CH, Lallos N, Georgiadis N, Kotsimpou A, Stewart JA. 24-hour intraocular pressures with brimonidine Purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology. 2005;112(4): 603–608. doi: 10.1016/j.ophtha.2004.11.032
29. Adkins JC, Balfour JA. Brimonidine. Drugs Aging. 1998;12(3): 225–241. doi: 10.2165/00002512-199812030-00005
30. Sullivan-Mee M, Pensyl D, Alldredge B, Halverson K, Gerhardt G, Qualls C. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations. J Ocul Pharmacol Therap. 2010;26(4): 355–360. doi: 10.1089/jop.2009.0153
31. Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW. Alpha(2)-adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther. 2001;296(1): 216–223.
32. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42(12): 2849–2855.
33. Mayor-Torroglosa S, Villa PD la, Rodriguez ME, Lopez-Herrera MPL, Aviles-Trigueros M, Garcia-Aviles A. Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidine. Invest Ophthalmol Vis Sci. 2005;46(10): 3825–3835. doi: 10.1167/iovs.05-0392
34. Tsai J-C, Chang H-W. Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study. J Ocular Pharmacol Ther. 2005;21(6): 475–482. doi: 10.1089/jop.2005.21.475
35. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol. 2011;151(4): 671–681. doi: 10.1016/j.ajo.2010.09.026
36. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005;62(7): 691–699. doi: 10.1093/ajhp/62.7.691
Страница источника: 94-99
Каталог
Продукции
Организации
Офтальмологические клиники, производители и поставщики оборудования
Издания
Периодические издания
Партнеры
Проекта Российская Офтальмология Онлайн